[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624644":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":32,"locations":38,"responsibleParty":62,"collaborators":21,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":21,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":21,"enrollmentInfo":73,"targetDuration":21,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Guangzhou Concord Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Proton therapy group","EXPERIMENTAL","All patients received proton therapy, with a prescribed dose of 60-66 Gy in 30-33 fractions, 5 days per week, for a total of 6-6.5 weeks.",[13,14],"Radiation: Proton therapy","Device: Proton radiation therapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","Proton therapy","Treatment planning and target delineation: All patients were in the supine position with the head extended backward, with the mask fixed, and enhanced computed tomography (CT) scans were performed for positioning. The slice thickness was 1.25mm. The gross tumor volume (GTV) included the recurrent primary lesion. The clinical target volume (CTV) included the anatomical expansion of the tumor and the suspicious lesions visible under the microscope. The CTV was defined as an expansion of 5-10mm outside the GTV. Radiation dose and treatment plan: The prescribed dose was 60-66 Gray (Gy) delivered in 30-33 fractions. Plan design and dose verification: The physicist designed radiotherapy plans according to the requirements of the physician. After the radiotherapy plan was designed, it was evaluated and repeatedly optimized by the physician and the physicist until satisfactory results were achieved. Treatment: was required for each treatment session.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DEVICE","Proton radiation therapy","Radiation: Proton Therapy System (ProBeam)",[9],[28],{"name":29,"affiliation":30,"role":31},"Yuan Taize","private hospital","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":21,"email":37},"Taize Yuan, M.D., Ph.D.","CONTACT","8620-32506195","taize.yuan@ccm.cn",[39,54],{"facility":5,"status":40,"city":41,"state":42,"zip":21,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Guangzhou","Guangdong","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":21,"phoneExt":21,"email":37},"Yuan taize, Doctor",{"facility":55,"status":40,"city":56,"state":41,"zip":21,"country":43,"countryCode":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":21},"Guangzhou concord cancer center","Guanzhou",{"type":46,"coordinates":58},[59,60],109.01843,28.41559,{"lat":60,"lon":59},{"type":63,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100624644","proton-therapy-for-recurrent-nasopharyngeal-carcinoma-100624644",false,"NCT07412314","Proton Therapy for Recurrent Nasopharyngeal Carcinoma","A Prospective Phase II Clinical Study of Proton Therapy for Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and\u002For with positive lymph nodes, (2) Pathological type WHO I-III\n2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1.\n\n   Age ≥ 18 years.\n3. Expected survival period ≥ 6 months\n4. Before treatment, evaluate the tumor range and size of the patient.\n5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy.\n\nExclusion Criteria:\n\n1. Evidence of distant metastasis in stage IVc\n2. Patients with isolated recurrence of cervical lymph nodes;\n3. Patients have participated in other interventional trials for tumors\n4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections","ALL","18 Years",{"count":74,"type":75},52,"ESTIMATED","INTERVENTIONAL",[78],"NA","The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.",[81],"Recurrent Nasopharyngeal Carcinoma",[83,84],"proton therapy","recurrent nasopharyngeal carcinoma","2026-03-05",{"date":87,"type":88},"2026-03-09","ACTUAL",{"date":90,"type":88},"2025-03-10",{"date":92,"type":75},"2028-03-10",{"name":5,"class":6},2]